AK-PENTOLATE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for AK-PENTOLATE (AK-PENTOLATE).
Antimuscarinic and anticholinergic agent that blocks muscarinic acetylcholine receptors, producing mydriasis and cycloplegia.
| Metabolism | Primarily hepatic via ester hydrolysis; metabolites are excreted renally. |
| Excretion | Renal 85% as unchanged drug; fecal 10% as metabolites; biliary 5%. |
| Half-life | Terminal elimination half-life 1.5-2 hours in adults; prolonged in neonates (up to 12 hours) due to immature hepatic and renal function. |
| Protein binding | 50-70% bound primarily to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | 0.2-0.4 L/kg; distributes into total body water; higher Vd in pediatric patients. |
| Bioavailability | Topical ophthalmic: approximately 10% systemic absorption via nasolacrimal duct; oral: 25-30% due to first-pass metabolism. |
| Onset of Action | Topical ophthalmic: 5-10 minutes for mydriasis; 30 minutes for cycloplegia. |
| Duration of Action | Mydriasis 6-12 hours; cycloplegia 12-24 hours. Complete recovery may take up to 48 hours. |
1 to 2 drops of 1% solution in the eye(s) every 5 to 10 minutes for 1 to 2 doses prior to examination.
| Dosage form | SOLUTION/DROPS |
| Renal impairment | No adjustment required; ophthalmic use has negligible systemic absorption. |
| Liver impairment | No adjustment required; ophthalmic use has negligible systemic absorption. |
| Pediatric use | Children: 1 drop of 0.5% or 1% solution 40 to 50 minutes before examination; may repeat in 20 to 30 minutes for adequate cycloplegia. |
| Geriatric use | Use lowest effective dose; caution for increased intraocular pressure risk. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for AK-PENTOLATE (AK-PENTOLATE).
| Breastfeeding | Excretion into breast milk unknown; due to risk of anticholinergic effects in infant, use caution and only if clearly needed. M/P ratio not established. |
| Teratogenic Risk | Anticholinergic effects may cause fetal tachycardia; no adequate studies in pregnant women. Avoid in first trimester if possible. Fetal risk cannot be excluded. |
| Fetal Monitoring | Monitor maternal heart rate and blood pressure; fetal heart rate monitoring recommended with prolonged use or high doses. |
■ FDA Black Box Warning
None
| Serious Effects |
["Narrow-angle glaucoma or anatomically narrow angles","Hypersensitivity to cyclopentolate or any component"]
| Precautions | ["Elevated intraocular pressure in patients with narrow-angle glaucoma","May cause CNS effects (e.g., somnolence, confusion) especially in children","Photosensitivity due to mydriasis"] |
| Food/Dietary | No specific food interactions. However, because the drug may cause anticholinergic effects like dry mouth, patients should avoid excessive caffeine or alcohol which can exacerbate these effects. |
| Clinical Pearls |
Loading safety data…
| Fertility Effects | No known adverse effects on fertility based on available data. |
| AK-PENTOLATE (cyclopentolate) is an anticholinergic ophthalmic agent used for mydriasis and cycloplegia. It has a faster onset and shorter duration than atropine but may cause systemic anticholinergic effects, especially in children and elderly. Use 1 drop of 0.5% or 1% solution; repeat in 5 minutes if needed. Avoid in patients with narrow-angle glaucoma. Monitor for central nervous system toxicity in infants. |
| Patient Advice | Wash hands before and after eye drop administration. · Avoid touching the dropper tip to prevent contamination. · Apply pressure to the inner corner of the eye (nasolacrimal occlusion) for 1 minute after instillation to reduce systemic absorption. · May cause blurred vision and photophobia; wear sunglasses and avoid driving until vision clears. · Discontinue use and contact doctor if eye pain, redness, or vision changes occur. · Do not use while wearing contact lenses; remove before instillation and wait 15 minutes before reinserting. |